Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial: An observational study

Circulation

Volumn 96, Issue 1, 1997, Pages 122-127

  Berger, Peter B ^a   Holmes Jr , David R ^a   Stebbins, Amanda L ^b   Bates, Eric R ^c   Califf, Robert M ^b   Topol, Eric J ^d  

^a MAYO CLINIC   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiography; Angioplasty; Infarction; Reperfusion; Shock

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOGENIC SHOCK; CORONARY ARTERY DILATATION; DRUG USE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0030754006     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.122     Document Type: Article

References (12)

1. Holmes DR Jr, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol EJ. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol. 1995;26:668-674.
2. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
3. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;1:525-530.
4. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation. 1988;78:1345-1351.
5. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O'Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long term survival. J Am Coll Cardiol. 1991;17:599-603.
6. Disler L, Haitas B, Benjamin J, Steingo L, McKibbon J. Cardiogenic shock in evolving myocardial infarction: treatment by angioplasty and streptokinase. Heart Lung. 1987;16:649-652.
7. Verna E, Repetto S, Boscarini M, Ghezzi I, Binaghi G. Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction. Eur Heart J. 1989;10:58-66.
8. Meyer P, Blanc P, Baudouy M, Morand P. Treatment de choc cardiogenique primaire par angioplastie transluminale coronarienne a la phase aigue de l'infarctus. Arch Mal Coeur. 1990;83: 329-334.
9. Hibbard M, Holmes DR Jr, Bailey KR, Reeder GS, Bresnahan JF, Gersh BS. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol. 1992;19: 636-649.
10. Hochman JS, Boland J, Sleeper JA, Porway M, Brinker J, Col J, Jacobs A, Slater J, Miller D, Wasserman H, Menegus MA, Talley JD, McKinlay S, Sanborn T, LeJemtel T, and the SHOCK Registry Investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Circulation. 1995;91:873-881.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
12. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.